{
    "clinical_study": {
        "@rank": "159665", 
        "acronym": "PopCorn", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A", 
                "description": "Children aged 12-15 months at the time of the study.  Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort."
            }, 
            {
                "arm_group_label": "Cohort B", 
                "description": "Children aged 24-27 months at the time of the study.  Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort."
            }
        ], 
        "brief_summary": {
            "textblock": "The present study is conducted in order to assess the acceptability of Hepatitis B\n      vaccination in French general population before and after reimbursement of the paediatric\n      vaccine InfanrixHexa. Four measurements are planned, first before reimbursement and the\n      others at year 1, 2 and 3 after reimbursement."
        }, 
        "brief_title": "Acceptability of Hepatitis B Vaccination in General Population", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "detailed_description": {
            "textblock": "The present study aims to evaluate the changes in Hepatitis B immunization coverage and the\n      acceptability thereof among parents, in the general population. This is a national,\n      prospective, epidemiological study, comprising four measurement time-points over a\n      three-year period, (T1 in 2009, T2 in 2010, T3 in 2011, and T4 in 2012) in order to cover\n      the period prior to the introduction of InfanrixHexa\u00ae reimbursement, the transition period,\n      and the period following reimbursement of the vaccine. The periods between each data\n      collection time-point will be identical, lasting a year. Two age groups will be investigated\n      at each data collection time-point: 12-15 months and 24-27 months, thus providing\n      measurements before/after reimbursement."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Infants aged 12 to 15 months or 24 to 27 months inclusive at the time of the study.\n\n          -  With a parent or legal representative agreeing to take part in the interview.\n\n          -  Residing in metropolitan France.\n\n        Exclusion Criteria:\n\n          -  Refusal to take part.\n\n          -  Infants having lived in another country in their first two years of life."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "27 Months", 
            "minimum_age": "12 Months", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The study population will consist of parents (with infants) agreeing to take part in a\n        personal interview."
            }
        }, 
        "enrollment": {
            "#text": "2413", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01782794", 
            "org_study_id": "113269"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort B", 
                "Cohort A"
            ], 
            "description": "Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.", 
            "intervention_name": "Data collection", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vaccination", 
            "Acceptability", 
            "General population", 
            "Hepatitis B", 
            "Vaccine coverage"
        ], 
        "lastchanged_date": "January 31, 2013", 
        "number_of_groups": "2", 
        "official_title": "Measurement of the Changes in Hepatitis B Immunization Coverage in Infants, and the Acceptability Thereof, Before Reimbursement, Then During the Three Years After Reimbursement of InfanrixHexa\u00ae in France, Among the General Population", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Haute Autorit\u00e9 de sant\u00e9 (HAS)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Proportion of infants receiving Hepatitis B vaccination.", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01782794"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The vaccination coverage by other vaccines will be described for each time point (i.e. at the initial time point, and at the years 1, 2 and 3 time points).", 
                "measure": "Evaluation of the immunization coverage levels by other vaccines.", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Acceptability of vaccinating against hepatitis B will be evaluated via assessment of the variation of this acceptability amongst parents categorised as \"accepting\", using their responses to a semi-qualitative questionnaire about vaccination.", 
                "measure": "Acceptability of vaccinating against Hepatitis B.", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2009", 
        "study_design": "Observational Model: Family-Based, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}